Specifically, this paper discusses the efficacy of currently published treatments of RPC and the successful use of an anti-IL-6 agent (i.e., tocilizumab) for the first time, to our knowledge, to control the disease. Here, IL6 is linked to familial reactive perforating collagenosis.